114 related articles for article (PubMed ID: 25911273)
1. Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time.
Torre C; Guerreiro J; de Oliveira Martins S; Raposo JF; Martins AP; Leufkens H
Prim Care Diabetes; 2015 Dec; 9(6):482-9. PubMed ID: 25911273
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic medications use trends in an Andalusian region from 2001 to 2014.
López-Sepúlveda R; García Lirola MÁ; Espínola García E; Jurado Martínez JM; Martín Sances S; Anaya Ordóñez S; Cabeza Barrera J
Prim Care Diabetes; 2017 Jun; 11(3):254-264. PubMed ID: 28126469
[TBL] [Abstract][Full Text] [Related]
3. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
4. Prescription patterns and costs of antidiabetic medications in a large group of patients.
Gaviria-Mendoza A; Sánchez-Duque JA; Medina-Morales DA; Machado-Alba JE
Prim Care Diabetes; 2018 Apr; 12(2):184-191. PubMed ID: 29196125
[TBL] [Abstract][Full Text] [Related]
5. Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study.
Bang C; Mortensen MB; Lauridsen KG; Bruun JM
Diabetes Obes Metab; 2020 Feb; 22(2):167-172. PubMed ID: 31486269
[TBL] [Abstract][Full Text] [Related]
6. Approaches to treatment 1: How is type 2 diabetes actually treated?
Bloomgarden ZT
J Diabetes; 2015 Nov; 7(6):747-8. PubMed ID: 26211568
[No Abstract] [Full Text] [Related]
7. Use of glucose-lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose-lowering drug groups.
Csatordai M; Benkő R; Matuz M; Bor A; Lengyel C; Doró P
Diabet Med; 2019 Dec; 36(12):1612-1620. PubMed ID: 31456231
[TBL] [Abstract][Full Text] [Related]
8. A cross-country utilization patterns comparison of high expenditure therapeutic groups between Portugal and six European countries: the two sides of the Portuguese coin.
Martinho I; Teixeira Rodrigues A; Guerreiro J; Rocha J; Sepodes B; Torre C
Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):89-97. PubMed ID: 36345962
[TBL] [Abstract][Full Text] [Related]
9. Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark.
Mortensen MB; Falk E; Schmidt M
Circ Cardiovasc Qual Outcomes; 2017 Jul; 10(7):. PubMed ID: 28698192
[No Abstract] [Full Text] [Related]
10. Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data.
Chin KL; Hidayat FM; Ofori-Asenso R; Ilomäki J; Bell JS; Zoungas S; Liew D
Drugs Aging; 2020 May; 37(5):393-398. PubMed ID: 32227290
[TBL] [Abstract][Full Text] [Related]
11. Regional differences in insulin therapy regimens in five European countries
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 May; 55(5):403-408. PubMed ID: 28257286
[TBL] [Abstract][Full Text] [Related]
12. [Use of glucose-lowering drugs in a primary care setting in Malaga during the years 2008-2012].
Mancera-Romero J; Hormigo-Pozo A; Fernández-Arquero J; Baca-Osorio A; Aparicio-Cervantes MJ; Muñoz-González L
Semergen; 2014; 40(1):4-11. PubMed ID: 24210521
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Resynchronization Therapy: US Trends and Disparities in Utilization and Outcomes.
Sridhar AR; Yarlagadda V; Parasa S; Reddy YM; Patel D; Lakkireddy D; Wilkoff BL; Dawn B
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003108. PubMed ID: 26921376
[TBL] [Abstract][Full Text] [Related]
14. [The increase in the use of drug treatment for diabetes mellitus in the Netherlands, 1998-2003].
Langendam MW; Hooijkaas C; Piepenbrink JF
Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1396-401. PubMed ID: 16841589
[TBL] [Abstract][Full Text] [Related]
15. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
Štuhec M; Locatelli I; Švab V
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
[TBL] [Abstract][Full Text] [Related]
16. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008.
Currie CJ; Peters JR; Evans M
Diabet Med; 2010 Jul; 27(7):744-52. PubMed ID: 20636954
[TBL] [Abstract][Full Text] [Related]
17. Rational use of blood glucose test strips for self-monitoring in patients with diabetes mellitus: Economic impact in the Portuguese healthcare system.
Risso T; Furtado C
Diabetes Res Clin Pract; 2017 Dec; 134():161-167. PubMed ID: 28951334
[TBL] [Abstract][Full Text] [Related]
18. [Antidiabetic drugs and in-patient admissions attributable to diabetes in Portugal].
Gouveia M; Laires P; Borges M; Augusto M; Martins AP
Acta Med Port; 2012; 25(5):323-31. PubMed ID: 23211204
[TBL] [Abstract][Full Text] [Related]
19. The Human Factor: The Cost of Switching from Analog to Human Insulin.
Tsai A
Diabetes Forecast; 2017 Mar; 70(2):44-47. PubMed ID: 29897684
[No Abstract] [Full Text] [Related]
20. Trends in practice of blood glucose control in critically ill patients in the Netherlands.
van Hooijdonk RT; Eslami S; de Keizer NF; Bakhshi-Raiez F; Bosman RJ; Dongelmans DA; van der Voort PH; Streefkerk JO; Engelbrecht WJ; ten Cate J; Huissoon S; van Driel EM; van Dijk I; Cimic N; Beck OF; Snellen FT; Holman ND; Mulder HC; Abu-Hanna A; Schultz MJ
Neth J Med; 2015 Dec; 73(10):455-63. PubMed ID: 26687261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
